-
Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results
Corre, J., Vincent, L., Moreau, P., Hebraud, B., Hulin, C., Béné, M.-C., Broijl, A., Caillot, D., Delforge, M., Dejoie, T., Facon, T., Lambert, J. R., Leleu, X., Macro, M., Perrot, A., Zweegman, S., Filleron, T., Cabarrou, B., van de Donk, N. W. C. J. & Mahéo, S. & 11 others, , 7 Aug 2025, In: Blood. 146, 6, p. 679-692 14 p.Research output: Contribution to journal › Article* › Academic › peer-review
-
The bone marrow NK-cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy
Korst, C. L. B. M., Tahri, S., Duetz, C., Bruins, W. S. C., de Jonge, A. V., de Jong, M. E., Fokkema, C., Smits, F., Groen, K., Verkleij, C. P. M., Frerichs, K. A., Papazian, N., van Duin, M., van Beek, G., Hoogenboezem, R., Baardemans, T., Dal Collo, G., Stoetman, E. C. G., Cosovic, M. & Twickler, I. & 15 others, , 19 Jun 2025, In: Blood. 145, 25, p. 3007-3014 8 p.Research output: Contribution to journal › Article* › Academic › peer-review
-
European Myeloma Network Group review and consensus statement on primary plasma cell leukemia
Musto, P., Engelhardt, M., van de Donk, N. W. C. J., Gay, F., Terpos, E., Einsele, H., Fernández de Larrea, C., Sgherza, N., Bolli, N., Katodritou, E., Gentile, M., Royer, B., Derudas, D., Jelinek, T., Zamagni, E., Rosiñol, L., Paiva, B., Caers, J., Kaiser, M. & Beksac, M. & 11 others, , Apr 2025, In: Annals of Oncology. 36, 4, p. 361-374 14 p.Research output: Contribution to journal › Review article* › Academic › peer-review
- All publications
